News
In this episode of Denatured, you’ll hear from Jack Crawford, CEO of Demeetra, and Magnus Gustavsson, chief commercial officer at NorthX Biologics. We unpack the evolution of cell line development — CHO cells, targeted integration, transposases and the collaboration models speeding biologics from sequence to GMP.
FEATURED STORIES
Psychedelics are gaining momentum in depression, with one treating physician predicting that the drug class could “wipe out the SSRIs” if safety and durability hold up.
Saol Therapeutics is the latest biotech to resubmit for approval of a drug rejected under former FDA Commissioner Marty Makary, following REGENXBIO and Replimune.
Even as FDA approvals for biologic therapies fell in the first half of 2026, regulatory experts are optimistic about a turnaround in the rare disease space after the departure of key leaders at the agency. Still, there will continue to be tension between science and politics.
FROM OUR EDITORS
Read our takes on the biggest stories happening in the industry.
Congressional letters sent to the CEOs of Eli Lilly, Pfizer, Merck, BMS and AbbVie this week voicing concerns about the pharmas’ clinical trials in China highlight an ongoing discrepancy in how government and industry think about the rise of the Asian country’s biotech industry.
THE LATEST
Even as Novartis entertains the potential sale of Sandoz, the company is lauding growth in its biosimilars business that is expected to stabilize its future development.
The portfolio of STING inhibitors is designed to treat autoimmune and inflammatory diseases.
Details about the U.S. government’s contract with Pfizer for 10 million doses of Paxlovid are emerging, with some unusual elements.
In a new “Measuring the Return from Pharmaceutical Innovation” report by Deloitte’s Center for Health Solutions, returns from R&D innovation are up by 7% across the industry.
Regeneron and Sanofi’s anti-inflammatory drug Dupixent has shown to be effective against five types of type 2 inflammations, with more indications expected to surface soon.
This week, Gilead Sciences took a $1.25 billion hit after reaching a settlement with ViiV Healthcare on a patent dispute involving the HIV drug dolutegravir.
Pfizer announced that Dr. William Pao, M.D., Ph.D., will take on the role of executive vice president and chief development officer as of March 21.
Recent FDA approval of ViiV Healthcare’s HIV treatment Cabenuva reduced dosing to once every two months.
OcuTerra Therapeutics aims to exchange watching and waiting for active treatment with a non-invasive eyedrop that reaches the retina and, therefore, allows treatment to occur much earlier in the disease.
Various pharmaceutical companies announced collaborations and licensing agreements from January 31 to February 1.